natgillin/translations-raw huggingface dataset:
Kun en patient, som skiftede til Sifrol depottabletter, fik en lægemiddelrelateret bivirkning, der medførte seponering. 
Only one patient switched to SIFROL prolonged-release tablets experienced a drug-related adverse event leading to withdrawal.
Den potentielle indflydelse af nedsat leverfunktion på Sifrols farmakokinetik kendes ikke. 
However, the potential influence of hepatic insufficiency on SIFROL pharmacokinetics has not been investigated.
I et placebo-kontrolleret polysomnografi-studie over 3 uger reducerede Sifrol signifikant antallet af periodiske benbevægelser, mens forsøgspersonerne var sengeliggende. 
In a placebo-controlled polysomnography study over 3 weeks SIFROL significantly reduced the number of periodic limb movements during time in bed.
Sifrol depottabletter var non-inferior i forhold til pramipexoltabletter vurderet ud fra UPDRS del II+III score ved uge 33. 
SIFROL prolonged-release tablets were non-inferior to pramipexole immediate release tablets as assessed on the UPDRS Parts II+III score at week 33.
Sikkerhed og virkning af Sifrol depottabletter ved behandling af Parkinsons sygdom blev undersøgt i et multinationalt klinisk udviklingsprogram bestående af 3 randomiserede, kontrollerede studier. 
The safety and efficacy of SIFROL prolonged-release tablets in the treatment of Parkinson's disease was evaluated in a multinational drug development program consisting of three randomised, controlled trials.
Ved kreatininclearance mindre end 30 ml/min anbefales det ikke at anvende Sifrol depottabletter, da der ikke findes data for denne patientpopulation. 
The treatment of patients with a creatinine clearance below 30 ml/min with SIFROL prolonged-release tablets is not recommended as no data are available for this patient population.
Den maksimale plasmakoncentration opnås ca. 6 timer efter administration af Sifrol depottabetter givet en gang daglig. 
The maximum plasma concentrations occur at about 6 hours after administration of SIFROL prolonged-release tablets once daily.
Sifrol kan påvirke evnen til at føre motorkøretøj og betjene maskiner i væsentlig grad. 
SIFROL can have a major influence on the ability to drive and use machines.
Du må ikke holde op med at tage SIFROL uden at spørge din læge til råds. 
Do not stop taking SIFROL without first talking to your doctor.
Når Sifrol gives i kombination med levodopa, anbefales det at reducere levodopa-dosis og at holde dosis af andre antiparkinson-lægemidler konstant, mens dosis af Sifrol øges. 
When SIFROL is given in combination with levodopa, it is recommended that the dose of levodopa is reduced and the dose of other anti-parkinsonian medicinal products is kept constant while increasing the dose of SIFROL.
Brug af SIFROL sammen med mad, drikke og alkohol Ved behandling med SIFROL, skal du være forsigtig med indtagelse af alkohol, da din reaktionsevne kan blive markant nedsat. 
SIFROL with food, drink and alcohol You should be cautious while drinking alcohol during treatment with SIFROL.
Det Europæiske Lægemiddelagentur har udsat forpligtelsen til at fremlægge resultaterne af studier med Sifrol i en eller flere undergrupper af den pædiatriske population med restless legs syndrom (se pkt. 
The European Medicines Agency has deferred the obligation to submit the results of studies with SIFROL in one or more subsets of the paediatric population in Restless Legs Syndrome (see section 4.2 for information on paediatric use).
SIFROL kan nedsætte mælkeproduktionen og kan også overføres til din baby via brystmælk. 
SIFROL can reduce the production of breast milk.
SIFROL må ikke anvendes under amning. 
SIFROL should not be used during breast-feeding.
Brug af anden medicin sammen med SIFROL 
Other medicines and SIFROL
Fortæl din læge, hvis du eller din familie/pårørende bemærker, at du er ved at udvikle mani (føle sig oprørt, opstemt eller ophidset) eller delirium (nedsat bevidsthed, forvirring eller manglende realitetsopfattelse). 
Tell your doctor if you or your family/carer notices that you are developing mania (agitation, feeling elated or over-excited) or delirium (decreased awareness, confusion, loss of reality).
Virkningen og tolerabiliteten hos patienter, som fra dag til dag skiftede behandling fra Sifrol tabletter til Sifrol depottabletter, blev undersøgt i et dobbelblindt klinisk studie hos patienter med tidlig udvikling af Parkinsons sygdom. 
The efficacy and tolerability of an overnight switch from SIFROL tablets to SIFROL prolongedrelease tablets at the same daily dose were evaluated in a double-blind clinical study in patients with early Parkinson's disease.
Patienter, som bliver behandlet med Sifrol, og som har oplevet døsighed, somnolens og/eller episoder med pludseligt opstået søvn, bør informeres om, at de skal afstå fra at køre bil eller deltage i aktiviteter, hvor nedsat årvågenhed kan udsætte dem eller andre for alvorlig fare eller død (f.eks. betjening af maskiner), indtil sådanne tilbagevendende episoder, døsighed og/eller somnolens er ophørt (se også pkt. 
Patients being treated with SIFROL and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes and somnolence have resolved (see also sections 4.4, 4.5 and 4.8).
Sifrol er indiceret til voksne til symptomatisk behandling af moderat til svær idiopatisk restless legs syndrom i doser op til 0,54 mg base (0,75 mg salt) (se pkt. 
SIFROL is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).
Almindelig (≥1/100 til <1/10) 
Common (≥1/100 to
Patienterne bør informeres om dette, og rådes til forsigtighed ved bilkørsel og betjening af maskiner. 
Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with SIFROL.
• Hallucinationer (at se, høre eller føle ting, som ikke er der) 
- Hallucinations (seeing, hearing or feeling things that are not there).
• Psykoser (f.eks. som ved symptomer på skizofreni) 
- Psychosis (e.g. comparable with symptoms of schizophrenia).
Skema for dosisøgning af Sifrol Uge 
Ascending dose schedule of SIFROL Week
Ved kreatininclearance mellem 30 og 50 ml/min bør behandlingen starte med 0,26 mg Sifrol depottabletter hver anden dag. 
In patients with a creatinine clearance between 30 and 50 ml/min, treatment should be started with 0.26 mg SIFROL prolonged-release tablets every other day.
SIFROL tabletter skal synkes hele med vand. 
Swallow the tablets whole with water.
Sjælden: Mani (føle sig oprørt, opstemt eller ophidset) 
Rare: - Mania (agitation, feeling elated or over-excited)
I et klinisk studie med raske frivillige forsøgspersoner, hvor dosisjustering af Sifrol depottabletter var hurtigere (hver 3. dag) end anbefalet, op til 3,15 mg pramipexolbase (4,5 mg salt)/dag, blev der observeret en stigning i blodtrykket samt en forøgelse af hjerterytmen. 
In a clinical trial with healthy volunteers, where SIFROL prolonged-release tablets were titrated faster (every 3 days) than recommended up to 3.15 mg pramipexole base (4.5 mg of salt) per day, an increase in blood pressure and heart rate was observed.
SIFROL bruges til 
What SIFROL is and what it is used for
Patienter og pårørende bør informeres om, at adfærdsmæssige symptomer på manglende impulskontrol herunder ludomani, forøget libido, hyperseksualitet, tvangshandlinger, der fører til overdrevent indkøbsmønster og uhæmmet og overdreven madindtagelse, kan forekomme hos patienter i behandling med dopaminagonister, herunder Sifrol. 
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including SIFROL.
Hvis du har glemt at tage en SIFROL dosis, men kommer i tanke om det indenfor 12 timer fra det sædvanlige tidspunkt, hvor du skulle have taget en dosis, skal du tage den sædvanlige tablet. 
If you forget to take a dose of SIFROL, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.
Patienter, der i forvejen tager Sifrol tabletter, kan fra dag til dag skifte til den samme daglige dosis af Sifrol depottabletter. 
Patients already taking SIFROL tablets may be switched to SIFROL prolonged-release tablets overnight, at the same daily dose.
Det skal du vide, før du begynder at tage SIFROL 
What you need to know before you take SIFROL
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med Sifrol i alle undergrupper af den pædiatriske population med Parkinsons sygdom (se pkt. 
The European Medicines Agency has waived the obligation to submit the results of studies with SIFROL in all subsets of the paediatric population in Parkinson's Disease (see section 4.2 for information on paediatric use).
Sifrols sikkerhed og virkning hos børn under 18 år er ikke klarlagt. 
The safety and efficacy of SIFROL in children below 18 years has not been established.
Sifrol anbefales ikke til børn og unge under 18 år p.g.a. manglende dokumentation for sikkerhed og virkning. 
SIFROL is not recommended for use in children and adolescents below 18 years due to a lack of data on safety and efficacy.
• Søvnighed og episoder med pludseligt indsættende søvn 
- Sleepiness and episodes of suddenly falling asleep.
SIFROL tabletter bør synkes med vand, og kan både tages sammen med eller uden mad. 
The tablets should be taken orally, swallowed with water, and can be taken either with or without food.
Alle tabletter har Boehringer Ingelheims firmalogo præget på den ene side og koden P6, P7, P8 eller P9 på den anden, hvilket repræsenterer tabletstyrker på henholdsvis 0,088 mg, 0,18 mg, 0,35mg og 0,7 mg. 
All tablets have the Boehringer Ingelheim company symbol embossed on one side and the codes P6, P7, P8, or P9 on the other side, representing the tablet strengths 0.088 mg, 0.18 mg, 0.35 mg, and 0.7 mg, respectively.
Det er ikke relevant at anvende Sifrol hos den pædiatriske population ved indikationen Parkinsons sygdom. 
There is no relevant use of SIFROL in the paediatric population for the indication of Parkinson's Disease.
Den anbefalede startdosis for Sifrol er 0,088 mg base (0,125 mg salt), som tages 1 gang dagligt 2-3 timer før sengetid. 
The recommended starting dose of SIFROL is 0.088 mg of base (0.125 mg of salt) taken once daily 2-3 hours before bedtime.
Hvis patienten glemmer en dosis, bør Sifrol depottabletter tages indenfor 12 timer fra det sædvanlige tidspunkt. 
When the intake of a dose is missed, SIFROL prolonged-release tablets should be taken within 12 hours after the regularly scheduled time.
Sifrol anbefales ikke til børn og unge under 18 år, da sikkerhed og virkning ikke er klarlagt hos denne population. 
SIFROL is not recommended for use in children and adolescents below 18 years since the efficacy and safety has not been established in this population.
Den daglige dosis bør ikke overstige 6 SIFROL tabletter á 0,088 mg eller en dosis af 0,54 mg (0,75 mg pramipexolsalt) 
The daily dose should not exceed 6 tablets SIFROL 0.088 mg or a dose of 0.54 mg (0.75 mg pramipexole salt).
Et dobbeltblindet, placebokontrolleret studie med 517 patienter med fremskreden Parkinsons sygdom, som samtidig blev behandlet med levodopa, viste, at Sifrol depottabletter havde en bedre virkning (superior) end placebo efter 18 ugers behandling på både det primære (UPDRS del II+III) og vigtigste sekundære (off-time) endepunkter. 
In a double-blind placebo-controlled trial including a total of 517 patients with advanced Parkinson's disease who were on concomitant levodopa therapy superiority of SIFROL prolonged-release tablets over placebo was demonstrated after 18 weeks of treatment on both the primary (UPDRS Parts II+III score) and the key secondary (off-time) efficacy endpoints.
Det er ikke relevant at anvende Sifrol depottabletter hos den pædiatriske population ved indikationen Parkinsons sygdom. 
There is no relevant use of SIFROL prolonged-release tablets in the paediatric population for the indication of Parkinson's Disease.
I den første uge er dosis oftest 1 SIFROL tablet á 0,088 mg tre gange dagligt (svarende til 0,264 mg om dagen): 
During the first week, the usual dose is 1 tablet SIFROL 0.088 mg three times a day (equivalent to 0.264 mg daily):
SIFROL påvirker nerveimpulser i hjernen, som kontrollerer kroppens bevægelser, ved at stimulere dopaminreceptorerne. 
Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.
Du kan både tage dem sammen med eller uden mad. 
You can take SIFROL with or without food.
SIFROL 1,05 mg, 1,57 mg, 2,1 mg, 2,62 mg og 3,15 mg depottabletter er hvide til råhvide og ovale. 
SIFROL 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg and 3.15 mg prolonged-release tablets are white to offwhite and of oval shape.
Ludomani, forøget libido, hyperseksualitet og tvangshandlinger, der fører til overdrevent indkøbsmønster og uhæmmet og overdreven madindtagelse, kan forekomme hos patienter i behandling med dopaminagonister, herunder Sifrol (se pkt. 
Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including SIFROL (see section 4.4).
SIFROL indeholder det aktive stof pramipexol, der er en såkaldt dopaminagonist, som stimulerer specielle receptorer i hjernen (dopaminreceptorerne). 
SIFROL contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain.
SIFROL 0,18 mg og SIFROL 0,35 mg er hvide, ovale og flade tabletter. 
SIFROL 0.18 mg tablets and SIFROL 0.35 mg tablets are white, of oval shape, and flat.
• Ved kreatininclearance mellem 20 og 50 ml/min bør initialdosis af Sifrol fordeles på 2 daglige doser begyndende med 0,088 mg base (0,125 mg salt) to gange dagligt svarende til 0,176 mg base (0,25 mg salt)/dag. 
In patients with a creatinine clearance between 20 and 50 ml/min, the initial daily dose of SIFROL should be administered in two divided doses, starting at 0.088 mg of base (0.125 mg of salt) twice a day (0.176 mg of base/0.25 mg of salt daily).
1 SIFROL tablet á 0,35 mg og 1SIFROL tablet á 0,18 mg 
1 tablet SIFROL 0.35 mg and 1 tablet SIFROL 0.18 mg
Din læge vil basere din dosis af SIFROL depottabletter på den dosis af almindelige SIFROL tabletter, som du hidtil har taget. 
If you are switching from SIFROL (immediate release) tablets Your doctor will base your dose of SIFROL prolonged-release tablets on the dose of SIFROL (immediate release) tablets you were taking.
Skema til øgning af dosis for Sifrol Titreringstrin 1 gang daglig Aften dosis (mg af base) 
Ascending dose schedule of SIFROL prolonged-release tablets Week Daily dose (mg of base)
1 SIFROL tablet á 0,7 mg og 1 SIFROL tablet á 0,35 mg 3 gange om dagen 
1 tablet SIFROL 0.7 mg and 1 tablet SIFROL 0.35 mg three times a day
Hvis din nyresygdom er moderat, er startdosis oftest 1 SIFROL tablet á 0,088 mg 2 gange daglig. 
If you have moderate kidney disease, the usual starting dose is 1 tablet SIFROL 0.088 mg twice a day.
SIFROL kan enten tages sammen med mad eller alene. 
SIFROL can be taken with or without food.
Sifrol kan gives, som monoterapi eller i kombination med levodopa i hele sygdomsforløbet herunder i de sene stadier, når virkningen af levodopa klinger af eller bliver ustabil, og svingninger i den terapeutiske virkning opstår. 
SIFROL is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).
SIFROL 0,7 mg er hvide, runde og flade tabletter. 
SIFROL 0.7 mg tablets are white, of round shape, and flat.
rastløshed, konfusion, hallucinationer, ændring af libido, vrangsforestillinger hyperfagi paranoia mani delirium usædvanlig adfærd med symptomer på manglende impulskontrol og tvangshandlinger (såsom overdrevent indkøbsmønster, ludomani, hyperseksualitet, uhæmmet fødeindtagelse) 
Psychiatric disorders insomnia abnormal dreams restlessness confusion hallucinations libido disorder delusion hyperphagia paranoia mania delirium behavioural symptoms of impulse control disorders and compulsions (such as: compulsive shopping, pathological gambling, hypersexuality, binge eating)
Hvis du har taget for mange SIFROL tabletter Hvis du har taget for mange SIFROL tabletter, så kontakt lægen eller skadestuen med det samme. 
If you accidentally take too many tablets, - Contact your doctor or nearest hospital casualty department immediately for advice.
Sådan skal du tage SIFROL 
How to take SIFROL
• Ved kreatininclearance mindre end 20 ml/min bør Sifrol gives som en enkeltdosis begyndende med 0,088 mg base (0,125 mg salt) per døgn. 
In patients with a creatinine clearance less than 20 ml/min, the daily dose of SIFROL should be administered in a single dose, starting at 0.088 mg of base (0.125 mg of salt) daily.
Ved fremskreden Parkinsons sygdom kan dyskinesi forekomme i optitreringsfasen med Sifrol, når det gives i kombination med levodopa. 
In advanced Parkinson's disease, in combination treatment with levodopa, dyskinesia can occur during the initial titration of SIFROL.
Dvs. hvis f.eks. kreatininclearance reduceres med 30%, så reduceres den daglige dosis tilsvarende med 30%. 
If renal function declines during maintenance therapy the SIFROL daily dose should be reduced by the same percentage as the decline in creatinine clearance, i.e. if creatinine clearance declines by 30%, then the SIFROL daily dose should be reduced by 30%.
• behandling af voksne patienter med symptomer på moderat til svær restless legs syndrom (RLS), en sygdom, der giver uro i benene. 
- treat the symptoms of moderate to severe primary Restless Legs Syndrome in adults.
SIFROL bruges til behandling af voksne patienter med symptomer på Parkinsons sygdom. 
SIFROL is used to treat the symptoms of primary Parkinson's disease in adults.
Sifrol 0,088 mg tabletter Sifrol 0,18 mg tabletter Sifrol 0,35 mg tabletter Sifrol 0,7 mg tabletter 
SIFROL 0.088 mg tablets SIFROL 0.18 mg tablets SIFROL 0.35 mg tablets SIFROL 0.7 mg tablets
Medicin mod psykiske lidelser (antipsykotika) må ikke tages sammen med SIFROL. 
You should avoid taking SIFROL together with antipsychotic medicines.
Afhængigt af den enkelte patients respons på behandlingen kan det anbefales, at levodopadosis reduceres både under dosisstigning og vedligeholdelsesbehandling med Sifrol (se pkt. 
It is recommended that the dose of levodopa is reduced during both the dose escalation and the maintenance treatment with SIFROL, depending on reactions in individual patients (see section 4.5).
Hvis du ikke kan undvære SIFROL, bør amningen stoppe. 
If use of SIFROL is unavoidable, breast-feeding should be stopped.
Afhængigt af patientens terapeutiske respons kan dosis af Sifrol depottabletter justeres efterfølgende (se pkt. 
After switching to SIFROL prolonged-release tablets, the dose may be adjusted depending on the patient's therapeutic response (see section 5.1).
• Hjertesvigt (hjerteproblemer, der kan forårsage åndenød eller hævede ankler)* 
Uncommon: - Urge to behave in an unusual way* - Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)* - Inappropriate antidiuretic hormone secretion*
Sifrol 0,088 mg tabletter 
SIFROL 0.088 mg tablets
Der er set færre svingninger i plasmakoncentrationen for pramipexol i løbet af 24 timer for Sifrol depottabletter givet en gang daglig end for Sifrol tabletter givet 3 gange daglig. 
The once daily administration of SIFROL prolonged-release tablets causes less frequent fluctuations in the pramipexole plasma concentration over 24 hours compared to the three times daily administration of pramipexole immediate release tablets.
SIFROL 0,088 mg tabletter SIFROL 0,18 mg tabletter SIFROL 0,35 mg tabletter SIFROL 0,7 mg tabletter pramipexol 
SIFROL 0.088 mg tablets SIFROL 0.18 mg tablets SIFROL 0.35 mg tablets SIFROL 0.7 mg tablets Pramipexole
Sifrol 0,35 mg tabletter 
SIFROL 0.35 mg tablets
Fortæl det til din læge, hvis du har eller har haft nogen af nedenstående sygdomme eller tilstande: 
Tell your doctor if you have (had) or develop any medical conditions or symptoms, especially any of the following: - Kidney disease.
SIFROL 0,26 mg og 0,52 mg depottabletter er hvide til råhvide, runde og har facetslebne kanter. 
What SIFROL looks like and contents of the pack SIFROL 0.26 mg and 0.52 mg prolonged-release tablets are white to off-white, of round shape, and have bevelled edges.
• Synsnedsættelse. 
- Vision impairment.
SIFROL 0,26 mg depottabletter SIFROL 0,52 mg depottabletter SIFROL 1,05 mg depottabletter SIFROL 1,57 mg depottabletter SIFROL 2,1 mg depottabletter SIFROL 2,62 mg depottabletter SIFROL 3,15 mg depottabletter pramipexol 
SIFROL 0.26 mg prolonged-release tablets SIFROL 0.52 mg prolonged-release tablets SIFROL 1.05 mg prolonged-release tablets SIFROL 1.57 mg prolonged-release tablets SIFROL 2.1 mg prolonged-release tablets SIFROL 2.62 mg prolonged-release tablets SIFROL 3.15 mg prolonged-release tablets
Sifrol 0,35 mg tabletter EU/1/97/050/011-012 
SIFROL 0.35 mg tablets EU/1/97/050/011-012
Sifrol 0,7 mg tabletter 
SIFROL 0.7 mg tablets
INFORMATION I BRAILLESKRIFT SIFROL 0,088 mg 
INFORMATION IN BRAILLE SIFROL 0.088 mg
Et fase-I studie, hvor pramipexoltabletter blev sammenlignet med pramipexoldepottabletter, viste ækvivalens mellem den samme døgndosis af Sifrol depottabletter givet en gang daglig og Sifrol tabletter givet 3 gange daglig for Cmin, Cmax og AUC. 
In a Phase I trial, where pramipexole immediate release and prolonged-release tablets were assessed in fasted state, the minimum and peak plasma concentration (Cmin, Cmax) and exposure (AUC) of the same daily dose of SIFROL prolonged-release tablets given once daily and SIFROL tablets given three times a day were equivalent.
Sifrol 0,7 mg tabletter EU/1/97/050/005-006 
SIFROL 0.7 mg tablets EU/1/97/050/005-006
Bivirkninger som søvnighed og pludselig indsættende søvn er set specielt for Parkinsonpatienter. 
SIFROL has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson's disease.
• feber 
Pneumonia
Sifrol 0,088 mg tabletter EU/1/97/050/001-002 
SIFROL 0.088 mg tablets EU/1/97/050/001-002
Børn og unge Børn og unge under 18 år bør ikke bruge SIFROL. 
Children and adolescents SIFROL is not recommended for use in children or adolescents under 18 years.
Sifrol 0,18 mg tabletter 
SIFROL 0.18 mg tablets
2 SIFROL tabletter á 0,18 mg 3 gange om dagen 
2 tablets SIFROL 0.18 mg three times a day
Hvis din nyresygdom er alvorlig, er startdosis oftest 1 SIFROL tablet á 0,088 mg 1 gang daglig. 
In severe kidney disease, the usual starting dose is just 1 tablet SIFROL 0.088 mg a day.
1 SIFROL tablet á 0,35 mg 
1 tablet SIFROL 0.35 mg OR
• Hallucinationer (ser, hører eller føler ting, som ikke er der). 
SIFROL can cause hallucinations (seeing, hearing or feeling things that are not there).
Sifrol 0,18 mg tabletter EU/1/97/050/003-004 
SIFROL 0.18 mg tablets EU/1/97/050/003-004
Sifrol kan ved behandling af restless legs syndrom (RLS) seponeres uden aftrapning, idet den daglige dosis ikke vil overstige 0,54 mg base (0,75 mg salt). 
Since the daily dose for the treatment of Restless Legs Syndrome will not exceed 0.54 mg of base (0.75 mg of salt) SIFROL can be discontinued without tapering off.
INFORMATION I BRAILLESKRIFT SIFROL 0,35 mg 
INFORMATION IN BRAILLE SIFROL 0.35 mg
1 SIFROL tablet á 0,35 mg 3 gange om dagen 
1 tablet SIFROL 0.35 mg three times a day OR
2 SIFROL tabletter á 0,088 mg 3 gange om dagen 
2 tablets SIFROL 0.088 mg three times a day
INFORMATION I BRAILLESKRIFT SIFROL 0,18 mg 
INFORMATION IN BRAILLE SIFROL 0.18 mg
INFORMATION I BRAILLESKRIFT SIFROL 0,7 mg 
INFORMATION IN BRAILLE SIFROL 0.7 mg